These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24291100)

  • 1. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Nasr M; Selima E; Hamed O; Kazem A
    Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
    Noguchi R; Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Mitoro A; Tsujinoue H; Imazu H; Masaki T; Fukui H
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6038-45. PubMed ID: 14676130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
    J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y
    Oncol Rep; 2005 Mar; 13(3):491-5. PubMed ID: 15706423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.
    Wada H; Nagano H; Yamamoto H; Yang Y; Kondo M; Ota H; Nakamura M; Yoshioka S; Kato H; Damdinsuren B; Tang D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Sakon M; Dono K; Wakasa K; Monden M
    Liver Int; 2006 May; 26(4):414-23. PubMed ID: 16629644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Kawata M; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
    Clin Cancer Res; 2001 Apr; 7(4):1073-8. PubMed ID: 11309359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
    El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
    Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Toyohara M; Ikenaka Y; Kitade M; Kaji K; Yamazaki M; Yamao J; Mitoro A; Sawai M; Yoshida M; Fujimoto M; Tsujimoto T; Kawaratani H; Uemura M; Fukui H
    J Hepatol; 2009 Aug; 51(2):315-21. PubMed ID: 19501932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin Suppresses Hepatic Stellate Cell-Induced Hepatocarcinoma Angiogenesis and Invasion through Downregulating CTGF.
    Shao S; Duan W; Xu Q; Li X; Han L; Li W; Zhang D; Wang Z; Lei J
    Oxid Med Cell Longev; 2019; 2019():8148510. PubMed ID: 30800209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of two selenium sources on hepatocarcinogenesis and several angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats.
    Liu JG; Zhao HJ; Liu YJ; Liu YW; Wang XL
    J Trace Elem Med Biol; 2012 Oct; 26(4):255-61. PubMed ID: 22425635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Saber S; Mahmoud AAA; Goda R; Helal NS; El-Ahwany E; Abdelghany RH
    Toxicol Lett; 2018 Oct; 295():32-40. PubMed ID: 29859236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1.
    Bae MK; Kim SH; Jeong JW; Lee YM; Kim HS; Kim SR; Yun I; Bae SK; Kim KW
    Oncol Rep; 2006 Jun; 15(6):1557-62. PubMed ID: 16685395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Fukui H
    Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell expression patterns of CD147 in N-diethylnitrosamine/phenobarbital-induced mouse hepatocellular carcinoma.
    Lu M; Wu J; He F; Wang XL; Li C; Chen ZN; Bian H
    J Mol Histol; 2015 Feb; 46(1):79-91. PubMed ID: 25447507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma.
    Lee TK; Poon RT; Yuen AP; Ling MT; Wang XH; Wong YC; Guan XY; Man K; Tang ZY; Fan ST
    Clin Cancer Res; 2006 Dec; 12(23):6910-9. PubMed ID: 17145808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.